Seminars in Oncology
Volume 37, Issue 1 , Pages 60-64 , February 2010

Digitization and Its Discontents: Future Shock in Predictive Oncology

  • Richard J. Epstein

      Affiliations

    • Corresponding Author InformationAddress correspondence to Richard J. Epstein, MD, PhD, Level 5, deLacy Building, St Vincent's Clinical School, 390 Victoria St, Darlinghurst 2010 NSW, Australia

References 

  1. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. 2008;100:1204–1214
  2. Jorgensen JT. Are we approaching the post-blockbuster era? (Pharmacodiagnostics and rational drug development). Expert Rev Mol Diagn. 2008;8:689–695
  3. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol. 2008;26:1346–1354
  4. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res. 2008;14:5967–5976
  5. Epstein RJ. Unblocking blockbusters: using boolean text-mining to optimise clinical trial design and timeline for novel anticancer drugs. Cancer Inform. 2009;7:231–238
  6. Epstein RJ, Leung TW, Mak J, Cheung PS. Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center. Cancer Invest. 2006;24:367–373
  7. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  8. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  9. Schmid EF, Smith DA. R&D technology investments: misguided and expensive or a better way to discover medicines?. Drug Discov Today. 2006;11:775–784
  10. Epstein RA. Overdose—how excessive government regulation stifles pharmaceutical innovation. New Haven, CT: Yale University Press; 2006;
  11. Meinert CL. NIH multicenter investigator-initiated trials: an endangered species?. Control Clin Trials. 1988;9:97–102
  12. Bell J. Resuscitating clinical research in the United Kingdom. BMJ. 2003;327:1041–1043

PII: S0093-7754(09)00231-0

doi: 10.1053/j.seminoncol.2009.12.006

Seminars in Oncology
Volume 37, Issue 1 , Pages 60-64 , February 2010

Article Tools

* Image Usage & Resolution